for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Mauna Kea Technologies SAS

MKEA.PA

Latest Trade

1.58EUR

Change

0.01(+0.38%)

Volume

268,830

Today's Range

1.56

 - 

1.62

52 Week Range

1.41

 - 

3.33

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
1.57
Open
1.57
Volume
268,830
3M AVG Volume
4.12
Today's High
1.62
Today's Low
1.56
52 Week High
3.33
52 Week Low
1.41
Shares Out (MIL)
25.16
Market Cap (MIL)
35.97
Forward P/E
-3.17
Dividend (Yield %)
--

Latest Developments

More

Mauna Kea Technologies H1 Total Sales Grow To 3.9 Million Euros

Mauna Kea: Receipt Of 11.5 Million Euros Under New Financing Agreement With EIB

Mauna Kea Technologies Announces Exercise Of A Tranche Of 5 Million Euros With IPF Partners

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Mauna Kea Technologies SAS

Mauna Kea Technologies SAS, also known as Mauna Kea Technologies SA, is a France-based company active in the healthcare business sector. It specializes in designing, developing, and selling medical imaging tools and systems. The Company’s products, used mainly in endoscopy, are intended for viewing and detecting deficiencies in the gastrointestinal and respiratory systems, primarily focusing on patients suffering from cancer. The main product offered by the Company is Cellvizio, a probe-based Confocal Laser Endomicroscopy (pCLE) which is a system providing physicians and researchers with high resolution cellular images of tissue in a real-time structure. The Company has marketing authorizations in Thailand, the United Kingdom, the USA, Brazil, Chile, South Korea, Poland, Russia and Saudi Arabia, among others.

Industry

Medical Equipment & Supplies

Contact Info

9, rue d'Enghien

+33.1.48240345

https://www.maunakeatech.com/

Executive Leadership

Sacha Loiseau

Chairman of the Board

Robert L. Gershon

Chief Executive Officer, Director

Christophe Lamboeuf

Deputy Chief Executive Officer, Chief Financial Officer

Francois Lacombe

Chief Scientific Officer

Bruno Villaret

Vice President of International Sales

Key Stats

3.67 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (EUR)

2016

-0.550

2017

-0.490

2018

-0.510

2019(E)

-0.455
Price To Earnings (TTM)
--
Price To Sales (TTM)
5.32
Price To Book (MRQ)
4.90
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
88.44
LT Debt To Equity (MRQ)
80.92
Return on Investment (TTM)
-66.50
Return on Equity (TTM)
-53.82

Latest News

BRIEF-Mauna Kea Technologies Q1 Total Sales Down At EUR 1.0 Million

* Q1 TOTAL SALES EUR 1.0 MILLION VERSUS EUR 1.6 MILLION YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Mauna Kea Cellvizio Demonstrates Superior Identification Of Patients At Risk For Esophageal Cancer

* MAUNA KEA TECHNOLOGIES’ CELLVIZIO® DEMONSTRATES SUPERIOR IDENTIFICATION OF PATIENTS AT RISK FOR ESOPHAGEAL CANCER COMPARED TO CURRENT DIAGNOSTIC STANDARD

BRIEF-Mauna Kea Technologies Appoints Christophe Lamboeuf As Chief Financial Officer

* MAUNA KEA TECHNOLOGIES APPOINTS CHRISTOPHE LAMBOEUF, AN EXPERIENCED FINANCIAL EXECUTIVE, AS CHIEF FINANCIAL OFFICER Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

BRIEF-Mauna Kea Technologies Cash Position Of EUR 20.6 Million At Jan. 31

* FY NET LOSS EUR 10.2 MILLION VERSUS LOSS EUR 9.7 MILLION YEAR AGO

BRIEF-Mauna Kea Technologies Says Cellvizio Receives Positive Evaluation From Korean Health Authority

* ANNOUNCES CELLVIZIO RECEIVES POSITIVE EVALUATION FROM KOREAN HEALTH AUTHORITY

BRIEF-Mauna Kea Technologies appoints Olivier Regnard as CFO

* MAUNA KEA TECHNOLOGIES APPOINTS OLIVIER REGNARD AS DEPUTY CEO AND CHIEF FINANCIAL OFFICER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Mauna Kea Technologies announces worldwide commercialization of Cellvizio

* ANNOUNCED ON TUESDAY THAT UROLOGY DIVISION OF COOK MEDICAL HAS OFFICIALLY LAUNCHED WORLDWIDE COMMERCIALIZATION OF CELLVIZIO AS PART OF THE STRATEGIC PARTNERSHIP ANNOUNCED BY THE TWO COS AT END OF 2015

BRIEF-Mauna Kea Technologies: multicenter randomized controlled trial shows improved early stomach cancer detection with Cellvizio

* SAYS MULTICENTER RANDOMIZED CONTROLLED TRIAL SHOWS IMPROVED EARLY STOMACH CANCER DETECTION WITH CELLVIZIO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Mauna Kea Technologies announces benefits of using Cellvizio for characterizing upper urinary tract cancer

* MAUNA KEA TECHNOLOGIES: NEW PUBLICATION CONFIRMS BENEFITS OF USING CELLVIZIO FOR CHARACTERIZING UPPER URINARY TRACT CANCER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Mauna Kea Technologies announces new peer-reviewed publication on Cellvizio

* Mauna Kea Technologies announces new peer-reviewed publication reports further external validation of unmatched Cellvizio endomicroscopy performance and inter-observer agreement in the characterization of pancreatic cysts

BRIEF-Mauna Kea secures a 7.0 million euros debt financing

* Mauna Kea Technologies secures a 7.0 million euros ($7.49 million) debt financing Source text for Eikon:

BRIEF-Mauna Kea technologies appoints John Soto as chief operating officer

* Mauna Kea technologies appoints John Soto as chief operating officer

BRIEF-Mauna Kea Technologies secures equity financing facility

* Mauna Kea Technologies secures an equity financing facility to support its development

BRIEF-Mauna Kea Technologies gives update on cellvizio's efficacy

* Cellvizio's strong clinical efficacy in the prevention of certain pancreatic cancers confirmed by positive results from contact study presented at UEGW 2016

BRIEF-Mauna Kea Technologies announces launch of study on cellvizio in pediatric cardiac surgery

* Announces launch of first study on cellvizio in pediatric cardiac surgery Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

BRIEF-Mauna Kea technologies reports H1 2016 financial results

* H1 revenue 4.9 million euros ($5.47 million) versus 4.7 million euros year ago

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up